Merck KGaA Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Belen Garijo Lopez

Algemeen directeur

€10.5m

Totale compensatie

Percentage CEO-salaris	14.2%
Dienstverband CEO	9.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	6.1yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Belen Garijo Lopez's beloning veranderd ten opzichte van Merck KGaA's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	€3b
Jun 30 2024	n/a	n/a	€3b
Mar 31 2024	n/a	n/a	€3b
Dec 31 2023	€11m	€2m	€3b
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€3b
Mar 31 2023	n/a	n/a	€3b
Dec 31 2022	€11m	€2m	€3b
Sep 30 2022	n/a	n/a	€3b
Jun 30 2022	n/a	n/a	€3b
Mar 31 2022	n/a	n/a	€3b
Dec 31 2021	€9m	€1m	€3b
Sep 30 2021	n/a	n/a	€3b
Jun 30 2021	n/a	n/a	€3b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	€7m	€1m	€2b
Sep 30 2020	n/a	n/a	€2b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	€6m	€1m	€1b
Sep 30 2019	n/a	n/a	€1b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€938m
Dec 31 2018	€7m	€1m	€1b
Sep 30 2018	n/a	n/a	€2b
Jun 30 2018	n/a	n/a	€2b
Mar 31 2018	n/a	n/a	€2b
Dec 31 2017	€6m	€1m	€3b

Compensatie versus markt: De totale vergoeding ($USD 10.96M ) Belen } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Austrian markt ($USD 4.35M ).

Compensatie versus inkomsten: De vergoeding van Belen is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Belen Garijo Lopez (64 yo)

9.8yrs

Tenure

€10,527,000

Compensatie

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Belen Garijo Lopez	Chair of Executive Board & CEO	9.8yrs	€10.53m	geen gegevens
Helene von Roeder	CFO & Member of Executive Board	1.3yrs	€1.23m	geen gegevens
Kai Beckmann	CEO of Electronics & Member of the Executive Board	13.6yrs	€8.26m	geen gegevens
Peter Guenter	CEO of Healthcare Business & Member of Executive Board	3.8yrs	€5.58m	geen gegevens
Matthias Heinzel	CEO of Life Science Sector & Member of Executive Board	3.6yrs	€5.22m	geen gegevens
Barbara Weiland	Chief Compliance Officer	5.3yrs	geen gegevens	geen gegevens
Dietmar Eidens	Head of the Global HR Business Partner Organization	9.8yrs	geen gegevens	geen gegevens
Frank Gotthardt	Head of Corporate & Government Relations - Europe	15.4yrs	geen gegevens	geen gegevens
Marc Horn	Head of Life Science Controlling	no data	geen gegevens	geen gegevens
Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	7.6yrs	geen gegevens	geen gegevens
Hans-Joachim Neumann	Head of Integrated Supply Chain	6.1yrs	geen gegevens	geen gegevens
Tina Sandmann	Head of Internal Auditing	5.3yrs	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MRCK is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dietmar Oeter	Independent Member of Supervisory Board	10.5yrs	€50.80k	geen gegevens
Alexander Putz	Member of Supervisory Board	4.5yrs	€50.80k	geen gegevens
Stefan Palzer	Supervisory Board Member	less than a year	geen gegevens	geen gegevens
Barbara Lambert	Independent Member of Supervisory Board	1.3yrs	€30.50k	geen gegevens
Sascha Held	Vice Chair of Supervisory Board	5.6yrs	€89.30k	geen gegevens
Michael Kleinemeier	Independent Chairman of Supervisory Board	5.6yrs	€50.80k	geen gegevens
Anne Lange	Independent Member of Supervisory Board	5.6yrs	€50.80k	geen gegevens
Christian Raabe	Independent Member of Supervisory Board	5.6yrs	€65.80k	geen gegevens
Daniel Thelen	Independent Member of Supervisory Board	5.6yrs	€65.80k	geen gegevens
Simon Thelen	Independent Member of Supervisory Board	5.6yrs	€50.80k	geen gegevens
Birgit Biermann	Member of Supervisory Board	2.3yrs	€50.80k	geen gegevens
Katja Vila	Supervisory Board Member	less than a year	geen gegevens	geen gegevens

5.6yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MRCK wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Merck KGaA Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Merck KGaA Announces Executive Changes

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: EPS: €1.86 (vs €1.70 in 3Q 2023)

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings released: EPS: €1.40 (vs €1.62 in 2Q 2023)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

First quarter 2024 earnings released: EPS: €1.60 (vs €1.83 in 1Q 2023)

Merck KGaA, Annual General Meeting, Apr 25, 2025

Upcoming dividend of €2.20 per share

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Dividend of €2.20 announced

Full year 2023 earnings released: EPS: €6.49 (vs €7.65 in FY 2022)

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings released: EPS: €1.70 (vs €2.12 in 3Q 2022)

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Second quarter 2023 earnings released

Merck KGaA, Annual General Meeting, Apr 26, 2024

First quarter 2023 earnings released

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

Full year 2022 earnings released

Now 20% undervalued

Now 20% undervalued

Now 20% undervalued

Third quarter 2022 earnings released

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Second quarter 2022 earnings released

First quarter 2022 earnings released: EPS: €2.02 (vs €1.72 in 1Q 2021)

Upcoming dividend of €1.85 per share

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS €1.71 (vs €0.67 in 2Q 2020)

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Upcoming dividend of €1.40 per share

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations

New 90-day low: €133

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant